Low-to-moderate dose glucocorticoids in primary Sjögren’s syndrome patients on hydroxychloroquine/iguratimod therapy: a target trial emulation study
Authors:
- 13 April 2026
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (6) , 3485-3495
Abstract
Objective To evaluate whether low-to-moderate dose glucocorticoids provide additional benefit in primary Sjögren’s syndrome patients treated with hydroxychloroquine and/or iguratimod. Methods Using the Chinese Rheumatism Data Center database, we emulated a pragmatic trial including 395 patients with primary Sjögren’s syndrome treated between May 2016 and August 2025. All patients received hydroxychloroquine and/or iguratimod as background therapy. Patients were categorized by glucocorticoid use: HCQ/IGU plus glucocorticoid group (≤ 30 mg/day prednisone equivalent, n = 188) or HCQ/IGU group (n = 207). Primary outcome was ESSDAI score change at 1 month. Secondary outcomes included ESSPRI scores and laboratory parameters. Treatment effects were estimated using overlap weighting of propensity scores. Stratified analyses examined subgroups by baseline ESSDAI, IgG levels, and arthritis status. Results After propensity score weighting, baseline characteristics were well-balanced. At 1 month, glucocorticoids provided no additional benefit in ESSDAI change compared to hydroxychloroquine/iguratimod (Cohen’s d = − 0.12; 95% CI, − 0.32 to 0.08; p = 0.270). ESSPRI scores showed no improvement (Cohen’s d = − 0.20; 95% CI, − 0.39 to 0.00; p = 0.077). While glucocorticoids increased white blood cell counts (Cohen’s d = 0.57; p < 0.001) and decreased IgG levels (Cohen’s d = − 0.33; p = 0.004), these changes did not translate into clinical benefits. Stratified analyses revealed no additional benefit from glucocorticoids in any subgroup, including patients with higher disease activity (ESSDAI ≥ 5), elevated IgG, or arthritis. Conclusion Low-to-moderate dose glucocorticoids (≤ 30 mg/day prednisone equivalent) provide no additional short-term clinical benefit at 1-month follow-up in primary Sjögren’s syndrome patients receiving background hydroxychloroquine and/or iguratimod therapy. Key Points • Low-to-Moderate dose glucocorticoids show no additional benefit over hydroxychloroquine/iguratimod therapy in primary Sjögren's syndrome patients.Keywords
Funding Information
- The Chinese National Key Technology R&D Program, Ministry of Science and Technology ((2017YFC0907601)
- The Chinese National Key Technology R&D Program, Ministry of Science and Technology (2017YFC0907605))
- the CAMS Innovation Fund for Medical Sciences ((2021-I2M-1-005)
- the CAMS Innovation Fund for Medical Sciences (2022-I2M-1-004)
- the CAMS Innovation Fund for Medical Sciences (2023-I2M-2-005)
- the CAMS Innovation Fund for Medical Sciences (2023-I2M-C&T-B-018))
- the National High Level Hospital Clinical Research Funding ((2022-PUMCH-A-227)
- the National High Level Hospital Clinical Research Funding (2022-PUMCH-B-013)
- the National High Level Hospital Clinical Research Funding (2025-PUMCH-D-001))
This publication has 46 references indexed in Scilit:
- Novel and potential future therapeutic options in Sjögren's syndromeHeliyon, 2024
- Reporting of Observational Studies Explicitly Aiming to Emulate Randomized TrialsJAMA Network Open, 2023
- Characteristics and treatment responses of immune thrombocytopenia in patients with primary Sjögren syndromeInternational Immunopharmacology, 2023
- Renal tubular acidosis and associated factors in patients with primary Sjögren’s syndrome: a registry-based studyClinical Rheumatology, 2022
- Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren SyndromeJAMA Network Open, 2022
- Revisiting the JOQUER trial: stratification of primary Sjögren’s syndrome and the clinical and interferon response to hydroxychloroquineRheumatology International, 2021
- Overlap WeightingJAMA, 2020
- Clinically Significant Renal Involvement in Primary Sjögren's Syndrome: Clinical Presentation and OutcomeArthritis & Rheumatism, 2013
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009
- Sjögren's syndromeThe Lancet, 2005